These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 25871547)
1. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors. Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547 [TBL] [Abstract][Full Text] [Related]
3. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection. Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337 [TBL] [Abstract][Full Text] [Related]
4. Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors. Giroud C; Du Y; Marin M; Min Q; Jui NT; Fu H; Melikyan GB Assay Drug Dev Technol; 2017; 15(2):53-63. PubMed ID: 28322598 [TBL] [Abstract][Full Text] [Related]
6. HIV cell fusion assay: phenotypic screening tool for the identification of HIV entry inhibitors via CXCR4. Smith EB; Ogert RA; Pechter D; Villafania A; Abbondanzo SJ; Lin K; Rivera-Gines A; Rebsch-Mastykarz C; Monsma FJ J Biomol Screen; 2014 Jan; 19(1):108-18. PubMed ID: 23989454 [TBL] [Abstract][Full Text] [Related]
7. Is there a future for antiviral fusion inhibitors? Berkhout B; Eggink D; Sanders RW Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966 [TBL] [Abstract][Full Text] [Related]
8. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865 [TBL] [Abstract][Full Text] [Related]
9. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. Miyauchi K; Kozlov MM; Melikyan GB PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181 [TBL] [Abstract][Full Text] [Related]
10. HIV-1 Entry and Membrane Fusion Inhibitors. Xiao T; Cai Y; Chen B Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579 [TBL] [Abstract][Full Text] [Related]
11. An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. Herschhorn A; Finzi A; Jones DM; Courter JR; Sugawara A; Smith AB; Sodroski JG PLoS One; 2011; 6(11):e26731. PubMed ID: 22069466 [TBL] [Abstract][Full Text] [Related]
12. Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. Bradley J; Gill J; Bertelli F; Letafat S; Corbau R; Hayter P; Harrison P; Tee A; Keighley W; Perros M; Ciaramella G; Sewing A; Williams C J Biomol Screen; 2004 Sep; 9(6):516-24. PubMed ID: 15452338 [TBL] [Abstract][Full Text] [Related]
13. A high throughput Cre-lox activated viral membrane fusion assay identifies pharmacological inhibitors of HIV entry. Esposito AM; Cheung P; Swartz TH; Li H; Tsibane T; Durham ND; Basler CF; Felsenfeld DP; Chen BK Virology; 2016 Mar; 490():6-16. PubMed ID: 26803470 [TBL] [Abstract][Full Text] [Related]
14. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G Virol J; 2008 May; 5():56. PubMed ID: 18452606 [TBL] [Abstract][Full Text] [Related]
15. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications]. Azevedo-Pereira JM; Santos-Costa Q Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693 [TBL] [Abstract][Full Text] [Related]
16. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition. Panos G; Watson DC Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642 [TBL] [Abstract][Full Text] [Related]
17. Imaging-based assay for identification and characterization of inhibitors of CXCR4-tropic HIV-1 envelope-dependent cell-cell fusion. Kramer S; Buontempo P; Agrawal S; Ralston R J Biomol Screen; 2011 Jul; 16(6):668-75. PubMed ID: 21474836 [TBL] [Abstract][Full Text] [Related]
18. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay. Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649 [TBL] [Abstract][Full Text] [Related]
19. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Platt EJ; Durnin JP; Kabat D J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435 [TBL] [Abstract][Full Text] [Related]
20. Functional impact of HIV coreceptor-binding site mutations. Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]